首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   4946篇
  免费   204篇
  国内免费   89篇
耳鼻咽喉   20篇
儿科学   145篇
妇产科学   52篇
基础医学   1165篇
口腔科学   72篇
临床医学   289篇
内科学   946篇
皮肤病学   43篇
神经病学   136篇
特种医学   28篇
外科学   155篇
综合类   726篇
预防医学   963篇
眼科学   27篇
药学   277篇
中国医学   81篇
肿瘤学   114篇
  2023年   48篇
  2022年   105篇
  2021年   163篇
  2020年   215篇
  2019年   115篇
  2018年   136篇
  2017年   122篇
  2016年   116篇
  2015年   130篇
  2014年   270篇
  2013年   273篇
  2012年   279篇
  2011年   378篇
  2010年   282篇
  2009年   253篇
  2008年   232篇
  2007年   268篇
  2006年   250篇
  2005年   227篇
  2004年   169篇
  2003年   176篇
  2002年   126篇
  2001年   101篇
  2000年   113篇
  1999年   79篇
  1998年   63篇
  1997年   48篇
  1996年   57篇
  1995年   47篇
  1994年   48篇
  1993年   31篇
  1992年   29篇
  1991年   35篇
  1990年   26篇
  1989年   15篇
  1988年   19篇
  1987年   11篇
  1986年   7篇
  1985年   29篇
  1984年   25篇
  1983年   15篇
  1982年   17篇
  1981年   7篇
  1980年   9篇
  1979年   9篇
  1978年   8篇
  1974年   6篇
  1973年   12篇
  1972年   6篇
  1971年   6篇
排序方式: 共有5239条查询结果,搜索用时 15 毫秒
1.
With a 5.3% of the global population involved, hepatitis B virus (HBV) is a major public health challenge requiring an urgent response. After a possible acute phase, the natural history of HBV infection can progress in chronicity. Patients with overt or occult HBV infection can undergo HBV reactivation (HBVr) in course of immunosuppressive treatments that, apart from oncological and hem-atological diseases, are also used in rheumatologic, gastrointestinal, neurological and dermatological settings, as well as to treat severe acute respiratory syndrome coronavirus 2 infection. The risk of HBV reactivation is related to the immune status of the patient and the baseline HBV infection condition. The aim of the present paper is to investigate the risk of HBVr in those not oncological settings in order to suggest strategies for preventing and treating this occurrence. The main studies about HBVr for patients with occult hepatitis B infection and chronic HBV infection affected by non-oncologic diseases eligible for immunosuppressive treatment have been analyzed. The occurrence of this challenging event can be reduced screening the population eligible for immunosuppressant to assess the best strategies according to any virological status. Further prospective studies are needed to increase data on the risk of HBVr related to newer immunomodulant agents employed in non-oncological setting.  相似文献   
2.
Introduction and objectivesLiver cirrhosis is a major public health issue associated with high morbidity and mortality. The ANSWER trial showed that long-term human albumin (LTA) infusions led to significant reduction of complications and mortality in patients with uncomplicated ascites. The present study aimed to assess the incremental cost of cirrhosis patients treated with LTA plus standard medical treatment (SMT) versus those treated with SMT from the perspective of the Mexican Social Security Institute (IMSS).Material and methodsCost of illness for patients with cirrhosis and grade 2-3 ascites treated with SMT or with SMT and LTA (following the treatment regimen from ANSWER) over a one-year period was estimated according to the IMSS perspective. Rates of treatments, complications and hospitalizations were based on results from the ANSWER trial. Unit costs from IMSS were gathered from public sources and transformed to 2020 Mexican $ (Mex$).ResultsThe use of LTA is estimated to require additional annual expenditure derived from the pharmacological cost of human albumin and by the follow up visits required for LTA administration (Mex$28,128). However, this cost may potentially be counterbalanced by the reduction in paracentesis, cirrhosis-related complications and hospitalizations which would lead to cost savings of Mex$33,417 per patient/year.ConclusionsBased on the ANSWER trial results, our study suggests that LTA may result in improved clinical outcomes and reduced costs for the IMSS when administered to cirrhosis patients with uncomplicated ascites.  相似文献   
3.
4.
5.
背景:儿童新型冠状(新冠)病毒Omicron变异株流行期间,免疫抑制状态儿童新冠病毒清除时间定量分析研究较少。 目的:探讨新冠病毒Omicron株感染后免疫抑制和非免疫抑制儿童病毒清除的时间差别,为公共卫生政策制定和精准疫情防控措施提供临床数据。 设计:回顾性队列研究。 方法:以新冠病毒Omicron变异株感染住院患儿为队列人群,分为免疫抑制组和非免疫抑制组,免疫抑制分为绝对免疫抑制、相对免疫抑制和实施免疫抑制疗法,以免疫抑制组病例的性别、年龄和新冠病毒感染的分型与非免疫抑制组行1∶3匹配。以鼻咽拭子新冠病毒PCR检测拷贝数阈(Ct)值≥35为队列终点。 主要结局指标:新冠病毒清除时间。 结果:2022年4月12日至2022年5月12日在上海市新冠病毒感染定点收治医院符合本文共同纳入和排除标准的连续病例728例。免疫抑制组33例,其中绝对免疫抑制8例,相对免疫抑制23例,接受免疫抑制疗法2例(不包括绝对和相对免疫抑制患儿)。非免疫抑制组匹配后99例。2组临床症状、新冠病毒感染治疗和疫苗接种次数差异均无统计学意义。免疫抑制组和非免疫抑制组新冠病毒清除时间分别为(16.5±6.8)和(10.3±4.4)d,差异有统计学意义。免疫抑制组和非免疫抑制组新冠病毒感染轻型病例病毒清除时间分别为(14.0 ± 8.3)和(9.7 ± 3.1)d,普通型病例病毒清除时间分别为(18.3 ± 4.9)和(11.2 ± 5.9)d,差异均有统计学意义。2组单日病毒清除率在第9~14天时差异有统计学意义(P为0.005~0.039)。2组普通型病例单日病毒清除率在第10~15天时差异有统计学意义。免疫抑制组新冠病毒感染2周后核酸检测再次呈阳性3例(9%),临床分型均较前轻,3例均未接种新冠疫苗。 结论:Omicron株感染的免疫抑制患儿病毒清除时间较非免疫抑制患儿显著延长,主要反映在第9~14天,免疫抑制患儿病毒复阳风险高,提示需要更长的隔离时间和转阴后严格的病毒监测。  相似文献   
6.
《Vaccine》2022,40(26):3655-3663
We conducted preclinical studies in mice using a yeast-produced SARS-CoV-2 RBD subunit vaccine candidate formulated with aluminum hydroxide (alum) and CpG deoxynucleotides. This formulation is equivalent to the CorbevaxTM vaccine that recently received emergency use authorization by the Drugs Controller General of India. We compared the immune response of mice vaccinated with RBD/alum to mice vaccinated with RBD/alum + CpG. We also evaluated mice immunized with RBD/alum + CpG and boosted with RBD/alum. Mice were immunized twice intramuscularly at a 21-day interval. Compared to two doses of the /alum formulation, the RBD/alum + CpG vaccine induced a stronger and more balanced Th1/Th2 cellular immune response, with high levels of neutralizing antibodies against the original Wuhan isolate of SARS-CoV-2 as well as the B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 and (Delta) variants. Neutralizing antibody titers against the B.1.1.529 (BA.1, Omicron) variant exceeded those in human convalescent plasma after Wuhan infection but were lower than against the other variants. Interestingly, the second dose did not benefit from the addition of CpG, possibly allowing dose-sparing of the adjuvant in the future. The data reported here reinforces that the RBD/alum + CpG vaccine formulation is suitable for inducing broadly neutralizing antibodies against SARS-CoV-2, including variants of concern.  相似文献   
7.
背景 透射电子显微镜(TEM)是检测病毒的重要手段,传统TEM检测常依靠专家手工观察,操作步骤繁琐,且已有机器学习方法易受到背景、噪声的影响,导致病毒检测方法准确率差、效率低且耗时长。 目的 探讨增强图卷积神经网络(EGCN)对TEM图像中的病毒形态自动识别问题,以提高TEM病毒检测的效率。 方法 EGCN模型利用卷积神经网络(CNN)提取像素间的局部特征信息,并结合样本特征之间的最近邻关系利用图卷积网络(GCN)进行图特征学习。在模型优化中联合优化群体超分类损失和分类交叉熵损失以提高EGCN模型对病毒类别信息特征的提取能力,较CNN对TEM病毒图像特征具备更强的特征提取能力。 结果 通过不同方法在15类TEM病毒图像数据集上开展实验,EGCN达到3.40%的top-1错误率、1.88%的top-2错误率、96.65%的精确度和96.60%的召回率,并通过一系列对比实验表明EGCN模型可以有效避免TEM图像中背景、噪声等的影响,提高对病毒识别的准确率。 结论 EGCN可以有效解决病毒形态识别任务,为病毒的诊断提供重要的参考价值。  相似文献   
8.
《Vaccine》2022,40(6):934-944
Respiratory Syncytial Virus (RSV) remains a leading cause of severe respiratory disease for which no licensed vaccine is available. We have previously described the derivation of an RSV Fusion protein (F) stabilized in its prefusion conformation (preF) as vaccine immunogen and demonstrated superior immunogenicity in naive mice of preF versus wild type RSV F protein, both as protein and when expressed from an Ad26 vaccine vector. Here we address the question if there are qualitative differences between the two vaccine platforms for induction of protective immunity. In naïve mice, both Ad26.RSV.preF and preF protein induced humoral responses, whereas cellular responses were only elicited by Ad26.RSV.preF. In RSV pre-exposed mice, a single dose of either vaccine induced cellular responses and strong humoral responses. Ad26-induced RSV-specific cellular immune responses were detected systemically and locally in the lungs. Both vaccines showed protective efficacy in the cotton rat model, but Ad26.RSV.preF conferred protection at lower virus neutralizing titers in comparison to RSV preF protein. Factors that may contribute to the protective capacity of Ad26.RSV.preF elicited immunity are the induced IgG2a antibodies that are able to engage Fcγ receptors mediating Antibody Dependent Cellular Cytotoxicity (ADCC), and the induction of systemic and lung resident RSV specific CD8 + T cells. These data demonstrate qualitative improvement of immune responses elicited by an adenoviral vector based vaccine encoding the RSV preF antigen compared to the subunit vaccine in small animal models which may inform RSV vaccine development.  相似文献   
9.
ObjectivesThe BIV1-CovIran vaccine is highly effective against COVID-19. The neutralizing potency of all SARS-CoV-2 vaccines seems to be decreased against variants of concern. We assessed the sensitivity of the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants to neutralizing antibodies (NAbs) present in sera from individuals who had received the BIV1-CovIran candidate vaccine compared with an original Wuhan-related strain.MethodsThe ability of vaccine serum to neutralize the variants was measured using the conventional virus neutralization test. The correlation of spike (S) protein antibody and anti-receptor binding domain with neutralizing activity was investigated.ResultsThe current study demonstrated that 29 of 32 (90.6%; 95% CI: 75.0–98.0) of the vaccinees developed NAbs against a Wuhan-related strain. It is noteworthy that 28 (87.50%) and 24 of 32 (75%) of the recipients were able to produce NAbs against Alpha, Beta, and Delta variants, respectively. Serum virus-neutralizing titres for different SARS-CoV-2 strains were weakly correlated with anti–receptor binding domain antibodies (Spearman r = 36-42, p < 0.05), but not S-binding antibodies (p > 0.05).DiscussionAlthough there was a reduction in neutralization titres against the Alpha, Beta, and Delta variants compared with the Wuhan strain, BIV1-CovIran still exhibited potent neutralizing activity against the SARS-CoV-2 variants of concern.  相似文献   
10.
目的 了解我国5岁以下儿童小肠结肠炎耶尔森菌腹泻病例临床与病原学特征,分析其可能的感染来源,为小肠结肠炎耶尔森菌病的防控与诊断提供科学依据。 方法 收集2010—2020年间来自全国10个省市自治区哨点医院儿童腹泻标本、调查及回访问卷;对标本进行小肠结肠炎耶尔森菌的分离鉴定;菌株进行生物分型、血清型鉴定;毒力基因检测以及脉冲场凝胶电泳(pulsed field gel electrophoresis,PFGE)分型。 结果 2010—2020年共监测11 377例,分离到致病性小肠结肠炎耶尔森菌63株,包括61株O:3血清型、2株O:9血清型菌株,5岁以下腹泻儿童感染率0.55%(63/11 377)。不同性别儿童对致病性小肠结肠炎耶尔森菌的感染率差异无统计学意义,1~5岁感染率高于≤1岁病例(χ2=44.836,P<0.05),感染患儿中1~5岁发热比例高于≤1岁(χ2=11.508 ,P<0.05),随访病例未发现后遗症。我国儿童感染O:3血清型致病性小肠结肠炎耶尔森菌的PFGE带型存在多样性,优势带型为K6GN11C30021、K6GN11C30012。 结论 我国5岁以下儿童感染致病性小肠结肠炎耶尔森菌的生物血清型以3/O:3为主,偶有4/O:3与2/O:9。根据患儿感染特点与高发季节推测食源为主要感染来源,需进一步调查研究。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号